Read Post Market Analysis published at 4 pm everday. click here
  1. home
  2. Company
  3. Cipla
  4. Financials

Pivot Points
07 Jul 2020 03:33 PM IST
Name S3 S2 S1 Pivot Points R1 R2 R3
Fibonacci 620.97 626.72 630.27 636.02 641.77 645.32 651.07
Bollinger band (1,2) - 638.34 640.34 640.34 640.34 642.34 -

Technical Indicator
Name Value
Adx(14) 34.95
Rsi(14) 34.95
Stoch Rsi(14) 0.45
MACD(12,26) 4.36
Williams %R -89.48
ROC -4.84
Moving Averages
Period Simple Exponential
MA 9 637.58 638.21
MA 20 640.34 637.26
MA 50 623.31 612.27
MA 100 540.11 570.30
MA 200 499.95 536.05
Related News

Exclusive: COVID-19 drug Remdesivir in short supply, prices go up by 6x in black market

update 06 Jul 05:06 PM

While Cipla's drug is yet to be available in the market, Hetero's initial supply of 20,000 vials is almost nearly exhausted.

Share market update: 3 stocks hit 52-week lows on NSE

update 03 Jul 11:14 AM

However, Vedanta , Hindalco Inds., Cipla, IndusInd Bank and HDFC Bank were among the top losers.

Pharma major Mylan gets go-ahead to make remdesivir for 'restricted emergency use'

update 02 Jul 05:26 PM

Written informed consent of each patient is required before the use of the drug while active post-marketing surveillance data and reporting of serious adverse events have to be submitted. On June 21, Hetero and Cipla were given permission to manufacture and market the drug on the same conditions.

Share market update: Pharma shares dip; Cipla down over 2%

update 01 Jul 12:04 PM

The Nifty Pharma index was trading 1.33 per cent down at 9852.4.

Cipla and Glenmark top picks in the pharma space: Deven R Choksey

update 30 Jun 12:30 PM

‘Fortunately with market volatility, there are good opportunities to enter at low prices’

Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient

update 29 Jun 11:05 PM

Gilead has tied up with generic drugmakers based in India and Pakistan, including Cipla Ltd and Hetero Labs Ltd, to make and supply remdesivir in 127 developing countries. Cipla's version is priced at less than 5,000 Indian rupees ($66.24), while Hetero Lab's version is priced at 5,400 rupees.

Taking Stock: Lockdown extension, weak global cues weigh on D-St; Sensex below 35,000

update 29 Jun 05:22 PM

Top Nifty gainers included HUL, Cipla, Britannia Industries, and HDFC Bank.

Cipla, Boehringer Ingelheim to co-market 3 oral anti-diabetic drugs

update 29 Jun 03:30 PM

The three drugs are Oboravo (Empagliflozin), Oboravo Met (Empagliflozin Metformin) and Tiptengio (Empagliflozin Linagliptin).

Cipla shares gain 2% on partnership with a German firm for anti-diabetic drugs

update 29 Jun 03:28 PM

The stock has rallied 72 percent in last three months as pharma sector has been in focus during COVID-19 crisis

Share market update: Pharma shares mixed; Cipla up over 1%

update 29 Jun 11:57 AM

The Nifty Pharma index was trading 0.04 per cent up at 10142.25.


Open Zerodha account launch

( ₹ 20 / Trade )